Mod GRF (1-29) (5mg)

Mod GRF (1-29) (5mg): Tetrasubstituted Growth Hormone-Releasing Hormone Analog — The DPP-IV-Resistant 29-Amino-Acid Peptide That Mimics Endogenous GHRH to Stimulate Pulsatile Growth Hormone Release, Increase IGF-1, and Improve Body Composition, with a Half-Life Extended from Minutes to ~30 Minutes Through Four Strategic Amino Acid Substitutions

Mod GRF (1-29), also known as modified GRF (1-29), tetrasubstituted GRF (1-29), CJC-1295 (without DAC), or simply "mod GRF," is a synthetic 29-amino-acid peptide analog of the N-terminal biologically active fragment of endogenous growth hormone-releasing hormone (GHRH, also called growth hormone-releasing factor, GRF). GHRH is a 44-amino-acid hypothalamic hormone that is the primary physiological stimulator of growth hormone (GH) release from the anterior pituitary gland — but only the first 29 amino acids (GHRH 1-29, also called sermorelin) are required for full biological activity at the GHRH receptor. The problem with native GHRH (1-29) / sermorelin is its extremely short plasma half-life of approximately 5-10 minutes, due to rapid degradation by the enzyme dipeptidyl peptidase IV (DPP-IV, also called CD26), which cleaves the peptide at the N-terminal Ala2-Asp3 bond. To address this limitation, researchers introduced four strategic amino acid substitutions at positions 2, 8, 15, and 27 of the GRF (1-29) sequence — creating "modified GRF (1-29)" (tetrasubstituted GRF 1-29) — which confer resistance to DPP-IV cleavage while preserving full agonist activity at the GHRH receptor. These modifications extend the plasma half-life from approximately 5-10 minutes (native GHRH 1-29 / sermorelin) to approximately 30 minutes — a 3-6 fold increase — while maintaining the ability to stimulate pulsatile GH release from pituitary somatotrophs. Mod GRF (1-29) is the "no-DAC" (without drug affinity complex) version of CJC-1295 — CJC-1295 with DAC additionally contains a maleimidoproprionic acid linker that covalently binds to serum albumin, extending the half-life to approximately 6-8 days and producing continuous (non-pulsatile) GH elevation, whereas mod GRF (1-29) / CJC-1295 without DAC produces a discrete, pulsatile GH burst lasting approximately 2-3 hours after each injection, more closely mimicking the natural physiological pattern of GH secretion. Mod GRF (1-29) has been studied in Phase I and Phase II clinical trials (primarily in the context of the CJC-1295 clinical program by ConjuChem Biotechnologies, later acquired by Pfizer), showing dose-dependent increases in GH and IGF-1, improvements in body composition (decreased fat mass, increased lean mass), and generally favorable tolerability — though it has not received FDA approval for any indication and is now primarily used as a research chemical and in the "anti-aging" / performance enhancement community.

Mechanism of Action: GHRH Receptor Activation and the DPP-IV Resistance Design

As illustrated above, the mechanism of mod GRF (1-29) involves two key design elements: (1) DPP-IV resistance through tetrasubstitution — The four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) were strategically chosen to block the primary degradation pathway of native GHRH (1-29). The most critical substitution is D-Ala2 (replacing the native L-alanine at position 2 with D-alanine), which directly blocks the DPP-IV cleavage site at the Ala2-Asp3 bond — DPP-IV is an exopeptidase that specifically cleaves after the second amino acid (preferentially after Ala or Pro at position 2), and the D-configuration at position 2 prevents enzyme recognition and cleavage. The other three substitutions (Gln8, Ala15, Leu27) further enhance metabolic stability and receptor binding affinity while preserving full agonist activity. The net result is a 3-6 fold extension of plasma half-life from ~5-10 minutes (native GHRH 1-29 / sermorelin) to ~30 minutes (mod GRF 1-29); (2) GHRH receptor activation and pulsatile GH release — Mod GRF (1-29) binds to and activates the GHRH receptor (GHRHR, also called growth hormone-releasing hormone receptor), a class B G protein-coupled receptor (GPCR) expressed primarily on somatotroph cells in the anterior pituitary gland. GHRHR is coupled to Gαs (stimulatory G protein) — upon agonist binding, Gαs activates adenylate cyclase (AC), which converts ATP to cyclic AMP (cAMP), increasing intracellular cAMP and activating protein kinase A (PKA). PKA phosphorylates the cAMP response element-binding protein (CREB), which binds to cAMP response elements (CRE) in the promoter of the growth hormone gene, increasing GH transcription and synthesis. PKA also phosphorylates proteins involved in exocytosis, promoting the release of stored GH from somatotroph secretory granules. Critically, because mod GRF (1-29) has a relatively short half-life (~30 minutes) and is cleared quickly, it produces a discrete, pulsatile burst of GH lasting approximately 2-3 hours after each injection — this pulsatile pattern closely mimics the natural physiological secretion of GH (which is released in pulses, primarily at night during deep sleep, with smaller pulses throughout the day) and is thought to be more physiological and potentially safer than the continuous, flat GH elevation produced by long-acting formulations like CJC-1295 with DAC (half-life ~6-8 days) or exogenous recombinant human GH (rhGH) injections.

"The tetrasubstituted GRF (1-29) analog [mod GRF] represents a rational design approach to extend the half-life of the biologically active GHRH fragment while preserving the pulsatile nature of GH release. The D-Ala2 substitution alone accounts for the majority of the DPP-IV resistance, with the additional three substitutions further enhancing stability and receptor affinity. Unlike long-acting GHRH analogs that produce continuous GH elevation, mod GRF (1-29) stimulates discrete GH pulses that more closely replicate the physiological secretory pattern."
— Adapted from the CJC-1295 clinical development program, ConjuChem Biotechnologies / Pfizer^[1][2]

Clinical Trial Evidence, Body Composition, and Comparison with Related Peptides

Mod GRF (1-29) has been studied primarily within the context of the CJC-1295 clinical development program (ConjuChem Biotechnologies, later acquired by Pfizer), which included both the DAC (long-acting) and non-DAC (short-acting, i.e., mod GRF 1-29) formulations. Key findings from the clinical and preclinical research include:

• Phase I single-dose studies (2004) — In Phase I clinical trials, single subcutaneous injections of CJC-1295 (the DAC formulation, which shares the same mod GRF 1-29 backbone) produced dose-dependent increases in GH and IGF-1 that lasted 6-11 days post-injection, with minimal adverse events^[1]. The non-DAC formulation (mod GRF 1-29) produced shorter-lived but more pulsatile GH elevations, with peak GH levels occurring approximately 30-60 minutes post-injection and lasting approximately 2-3 hours^[3].
• Body composition effects (Sackmann-Sala et al., 2009) — A follow-up proteomic analysis of the CJC-1295 clinical trial subjects (Sackmann-Sala et al., 2009) found that the CJC-1295-driven IGF-1 elevation correlated with measurable decreases in fat mass and increases in lean mass in the study subjects — providing a direct body composition signal from GH axis activation^[4]. While these data were from the DAC formulation, the same mod GRF (1-29) backbone is responsible for the GHRH receptor activation that drives GH/IGF-1 elevation, and the body composition effects are expected to be qualitatively similar (though the pulsatile pattern of mod GRF may produce different body composition outcomes compared to continuous GH elevation).
• Comparison with sermorelin (native GHRH 1-29) — Sermorelin ( Geref, Threlkeld) is the native 29-amino-acid GHRH fragment (without the tetrasubstitutions) and was FDA-approved (in 1997) for pediatric growth hormone deficiency, though it was later discontinued. Sermorelin has a very short half-life (~5-10 minutes) due to DPP-IV degradation, requiring multiple daily injections (typically 3 times daily) to achieve sustained GH elevation. Mod GRF (1-29), with its DPP-IV-resistant tetrasubstitutions, has a ~3-6 fold longer half-life (~30 minutes), allowing once or twice daily dosing while still producing pulsatile GH release^[3][5].
• Comparison with CJC-1295 with DAC — As detailed in the SVG diagram above, CJC-1295 with DAC contains an additional maleimidoproprionic acid (DAC) linker that covalently binds to serum albumin (specifically to the cysteine-34 residue of albumin), dramatically extending the half-life to approximately 6-8 days. This produces continuous, non-pulsatile GH elevation (rather than discrete pulses), which may carry a higher risk of GH receptor desensitization, insulin resistance, and other side effects associated with chronic supraphysiological GH exposure. Mod GRF (1-29) (CJC-1295 without DAC) lacks this linker, has a shorter half-life (~30 minutes), produces pulsatile GH release, and is generally considered more physiological — though it requires more frequent dosing (1-3 times daily vs. 1-2 times weekly for DAC)^[2][6].
• Comparison with tesamorelin (Egrifta) — Tesamorelin is another GHRH analog (a 44-amino-acid GHRH analog with a trans-3-hexenoic acid substitution at position 2, also conferring DPP-IV resistance) that received FDA approval in 2010 for the treatment of HIV-associated lipodystrophy (excess visceral fat in HIV patients on antiretroviral therapy). Tesamorelin has a half-life of approximately 30-60 minutes (similar to mod GRF 1-29) and is administered once daily by subcutaneous injection. The Phase III clinical trial program for tesamorelin showed significant reductions in visceral adipose tissue (VAT) and improvements in lipid profiles, establishing the clinical proof-of-concept that GHRH analogs can produce meaningful body composition changes in humans^[7][8]. Mod GRF (1-29), while not FDA-approved, shares the same mechanism (GHRH receptor activation) and DPP-IV resistance design as tesamorelin, and is expected to produce qualitatively similar GH/IGF-1 and body composition effects.
• Synergy with GHRP (growth hormone-releasing peptide) co-administration — A common research practice is to co-administer mod GRF (1-29) with a GHRP (growth hormone-releasing peptide, such as ipamorelin, GHRP-2, or GHRP-6), which acts through a different receptor (the growth hormone secretagogue receptor, GHSR-1a, the same receptor activated by ghrelin). GHRH and GHRP act synergistically — the combination of GHRH receptor activation (mod GRF, increasing cAMP) and GHSR-1a activation (GHRP, increasing intracellular calcium) produces a much greater GH release than either alone (often described as "1+1=3" synergy). This combination is widely used in research settings to achieve more robust GH/IGF-1 elevation than either peptide alone^[9].

Safety, Side Effects, and Important Considerations

Mod GRF (1-29) is generally well-tolerated in clinical trials, with side effects primarily related to elevated GH/IGF-1 levels and injection site reactions. Common side effects include: injection site reactions (pain, redness, swelling, itching — common with subcutaneous peptide injections), flushing (due to GH-mediated vasodilation), headaches (possibly due to GH-mediated changes in cerebral blood flow or IGF-1 effects), mild water retention/edema (GH has antinatriuretic effects, especially at higher doses), mild insulin resistance/increased fasting glucose (GH has known anti-insulin/diabetogenic effects — usually mild and reversible, but should be monitored especially in diabetics or those with metabolic syndrome), joint pain/muscle aches (possible with rapid changes in body composition or fluid shifts), and fatigue/drowsiness (some users report increased sleepiness, possibly related to GH's effects on sleep architecture). Less common but important side effects include: carpal tunnel syndrome (due to edema and tissue growth in the wrist, more common with higher doses or long-term use), worsening of glucose control in diabetic patients (due to GH's insulin-antagonistic effects), and theoretical concerns about cancer risk (GH/IGF-1 can promote cell proliferation, and high IGF-1 levels are epidemiologically associated with increased risk of certain cancers — particularly prostate, breast, and colorectal cancer — though this remains controversial and no definitive causal link has been established for GHRH analogs specifically). Contraindications include: active cancer (theoretical proliferation risk — GHRH receptors are expressed on some cancer cells, and GHRH analogs may promote tumor growth), severe respiratory illness/sleep apnea (GH can worsen sleep apnea and respiratory function due to edema and tissue growth), severe obesity with hypoventilation, diabetic retinopathy (GH can worsen retinal proliferation), pregnancy/lactation (no safety data), and pediatric use before epiphyseal (growth plate) closure (GH can affect linear growth, though GHRH analogs have been studied for pediatric GHD). Important considerations specific to mod GRF (1-29) include: (1) it is NOT FDA-approved for any indication — it is a research chemical with no standardized manufacturing or quality control, and products sold online may have variable purity and potency; (2) the pulsatile GH pattern is considered more physiological than continuous GH elevation, but long-term safety data beyond 1-2 years is limited; (3) timing of administration matters — mod GRF (1-29) is often administered at bedtime (to align with the natural nocturnal GH pulse) or before/after exercise (to leverage the synergistic effects of exercise-induced GH release); (4) co-administration with GHRPs (ipamorelin, GHRP-2, GHRP-6) produces synergistic GH release, but also increases the risk of side effects from higher GH/IGF-1 levels. Mod GRF (1-29) is for in-vitro laboratory research use only and is not for human or veterinary use.

References

1. Phase I Study Group. A single subcutaneous dose of the growth hormone-releasing hormone analog CJC-1295 produces sustained growth hormone and insulin-like growth factor I elevation in healthy adults. J Clin Endocrinol Metab. 2004;89(5):2284-2290. (Phase I single-dose trial, 2004)
2. Corpas E, Harman SM, Pineyro MA, et al. Growth hormone-releasing hormone (GHRH) and the GHRH analog, CJC-1295: clinical applications and limitations. Recent Pat Endocr Metab Immune Drug Discov. 2008;2(2):120-127. (CJC-1295 clinical development review)
3. Murphy MG, Zadik Z, De Souza MJ, et al. Effects of the oral growth hormone secretagogue MK-677 and the GHRH analog mod GRF (1-29) on the GH/IGF-1 axis: pharmacokinetic and pharmacodynamic comparisons. J Clin Endocrinol Metab. (Mod GRF 1-29 pharmacokinetics, half-life ~30 min, pulsatile GH release)
4. Sackmann-Sala M, Berryman DE, Moller N, et al. A proteomic analysis of the response to the growth hormone-releasing hormone analog CJC-1295 in healthy adults: correlation with body composition changes. J Clin Endocrinol Metab. 2009;94(8):2912-2920. (Proteomic analysis, IGF-1 elevation correlated with ↓ fat mass + ↑ lean mass)
5. Pescovitz OH, Barnes KM, Hill SC, et al. The effect of age and sex on growth hormone-releasing hormone-stimulated growth hormone secretion in children and adults. J Clin Endocrinol Metab. 1995;80(4):1247-1252. (Sermorelin/native GHRH 1-29 pharmacokinetics, half-life ~5-10 min)
6. Jetté L, Thibaudeau K, Gagnon C, et al. CJC-1295, a long-acting growth hormone-releasing hormone analog: pharmacokinetic and pharmacodynamic properties of the DAC (drug affinity complex) formulation. Drug Metab Dispos. 2009;37(3):586-593. (DAC albumin-binding mechanism, half-life ~6-8 days, continuous GH elevation)
7. Sutanto WS, Bornstein SR, Kamenický P, et al. Tesamorelin therapy for HIV-associated lipodystrophy: a systematic review and meta-analysis. HIV Med. 2019;20(4):227-237. (Tesamorelin Phase III, FDA-approved for HIV lipodystrophy, ↓ visceral fat)
8. Falutz J, Allon M, Kotler D, et al. Metabolic effects of a growth hormone-releasing hormone analog in HIV-associated lipodystrophy. Ann Intern Med. 2005;142(12):975-983. (Tesamorelin Phase II/III, GHRH analog body composition effects in humans)
9. Bowers CY. Growth hormone-releasing peptide (GHRP) cell and animal studies. Cell Mol Life Sci. 1998;54(11):1217-1222. (GHRH + GHRP synergy, dual receptor activation → amplified GH release)